Pipeline
We are developing best-in-class copper-based therapeutics and companion diagnostics. Our pipeline comprises tumor indications with high medical need where our copper-based radiopharmaceuticals show a great potential for superior performance.
Program
Indication
Discovery
Preclinical
Phase 1
NuriPro ™
Prostate Cancer
TraceNET ™
Breast & Colorectal Cancer (SSTR+ve tumors)
Kalios ™
Lobular Breast & Lung Cancer Sarcoma
AlphaFlare ™
Undisclosed
Diagnostic (61Cu-X)
Therapeutic (67Cu-X)
NutriPro ™
Prostate Cancer
Discovery Preclinical Phase 1
61Cu-PSMA
67Cu-PSMA
TraceNET ™
Neuroendocrine Tumours (NET)
Discovery Preclinical Phase 1
61Cu-SSTR
67Cu-SSTR
Kalios ™
Breast & Lung Cancer
Discovery Preclinical Phase 1
61Cu-FAPI
67Cu-FAPI
AlphaFlare ™
Head & Neck Pancreatic Cancer
Discovery Preclinical Phase 1
61Cu-Integrin
67Cu-Integrin
Diagnostic (61Cu-X)
Therapeutic (67Cu-X)
1 in 8 men will be diagnosed with prostate cancer during their lifetime; 6 out of 10 cases are diagnosed in men 65 or older. The 5-year survival rate for local/regional cancer is 100% but drops drastically to 31% for metastatic cancer. Expression of the Prostate-Specific Membrane Antigen (PSMA) is up to 80 times higher in almost all prostate carcinoma tumours compared to healthy cells. NuriProTM binds specifically to PSMA, enabling precise diagnosis and targeted treatment. Our 61Cu-based NuriProTM diagnostic component enables a technique called delayed imaging, where even smallest metastases can be detected. Based on these imaging data, our 67Cu-based NuriProTM therapeutic can enable targeted treatment with an improved safety and efficacy profile and reduced radiation burden for the patient.
Breast cancer (BC) is the most frequent cancer affecting women and, with almost 2.3 million new cases per year, accounts for 11.5% of all new cancer diagnoses. Even though early breast cancer has a high 5-year survival probability (>90% in Europe and North America), metastatic breast cancer (mBC) is still an uncurable disease. The somatostatin subtype-2 receptor (SSTR2), an established tumor marker, represents an interesting new target for novel radiotherapy and diagnostics in mBC. Its expression is highest in tumors that are estrogen receptor-positive (ER+), progesterone receptor positive (PR+), and human epidermal growth factor receptor 2 negative (HER2-). Recent studies have demonstrated that SSTR2-antagonists have superior binding properties compared to prior agonist approaches, making them a promising ligand for theranostics that target tumors with varying SSTR2-expression. TraceNETTM is an SSTR2-antagonist with favorable binding properties and is currently being developed for patients living with mBC. The 61Cu-based TraceNETTM diagnostic component is highly specific and enables delayed imaging, which can detect even the smallest tumors at an early stage with reduced toxicity, as demonstrated in preclinical settings. Based on these imaging data, our 67Cu-based TraceNETTM therapeutic has the potential to enable targeted treatment with improved safety and efficacy at reduced radiation burden.
80 – 90% of all cancer cases are of epithelial origin, stemming from cells in the internal and external lining of the body. KaliosTM is targeting cells in the tumor microenvironment called cancer-associated fibroblasts, which are present in epithelial tumours such as breast and lung cancer and are not present in healthy tissues. Early detection of metastases in lymph nodes and crucial organs can increase the survival rate through early intervention. Unlike other tracers, our 61Cu-based KaliosTM diagnostic component can be used effectively in staging to detect nodal metastases in the liver and peritoneum.
AlphaFlareTM targets cell adhesion receptors, so called integrins, which mediate attachment of cells to other cells or matrix proteins as well as traction of the cell during movement. These receptors are overexpressed significantly in cells during the process of tumorigenesis, tumour progression and metastasis formation and are often associated with a poor prognosis. They are markers for aggressive forms of malignancies such as pancreatic cancer, lung cancer and breast cancer. Diagnostic imaging with AlphaFlareTM’s 61Cu-component allows for the early detection of nodal and distant metastases (correct staging), enabling the most optimal therapy according to the stage of the disease and receptor expression with our 67Cu-based AlphaFlareTM component.
Breast cancer (BC) is the most frequent cancer affecting women and, with almost 2.3 million new cases per year, accounts for 11.5% of all new cancer diagnoses. Even though early breast cancer has a high 5-year survival probability (>90% in Europe and North America), metastatic breast cancer (mBC) is still an uncurable disease. The somatostatin subtype-2 receptor (SSTR2), an established tumor marker, represents an interesting new target for novel radiotherapy and diagnostics in mBC. Its expression is highest in tumors that are estrogen receptor-positive (ER+), progesterone receptor positive (PR+), and human epidermal growth factor receptor 2 negative (HER2-). Recent studies have demonstrated that SSTR2-antagonists have superior binding properties compared to prior agonist approaches, making them a promising ligand for theranostics that target tumors with varying SSTR2-expression. TraceNETTM is an SSTR2-antagonist with favorable binding properties and is currently being developed for patients living with mBC. The 61Cu-based TraceNETTM diagnostic component is highly specific and enables delayed imaging, which can detect even the smallest tumors at an early stage with reduced toxicity, as demonstrated in preclinical settings. Based on these imaging data, our 67Cu-based TraceNETTM therapeutic has the potential to enable targeted treatment with improved safety and efficacy at reduced radiation burden.
1 in 8 men will be diagnosed with prostate cancer during their lifetime; 6 out of 10 cases are diagnosed in men 65 or older. The 5-year survival rate for local/regional cancer is 100% but drops drastically to 31% for metastatic cancer. Expression of the Prostate-Specific Membrane Antigen (PSMA) is up to 80 times higher in almost all prostate carcinoma tumours compared to healthy cells. NuriProTM binds specifically to PSMA, enabling precise diagnosis and targeted treatment. Our 61Cu-based NuriProTM diagnostic component enables a technique called delayed imaging, where even smallest metastases can be detected. Based on these imaging data, our 67Cu-based NuriProTM therapeutic can enable targeted treatment with an improved safety and efficacy profile and reduced radiation burden for the patient.
AlphaFlareTM targets cell adhesion receptors, so called integrins, which mediate attachment of cells to other cells or matrix proteins as well as traction of the cell during movement. These receptors are overexpressed significantly in cells during the process of tumorigenesis, tumour progression and metastasis formation and are often associated with a poor prognosis. They are markers for aggressive forms of malignancies such as pancreatic cancer, lung cancer and breast cancer. Diagnostic imaging with AlphaFlareTM’s 61Cu-component allows for the early detection of nodal and distant metastases (correct staging), enabling the most optimal therapy according to the stage of the disease and receptor expression with our 67Cu-based AlphaFlareTM component.
80 – 90% of all cancer cases are of epithelial origin, stemming from cells in the internal and external lining of the body. KaliosTM is targeting cells in the tumor microenvironment called cancer-associated fibroblasts, which are present in epithelial tumours such as breast and lung cancer and are not present in healthy tissues. Early detection of metastases in lymph nodes and crucial organs can increase the survival rate through early intervention. Unlike other tracers, our 61Cu-based KaliosTM diagnostic component can be used effectively in staging to detect nodal metastases in the liver and peritoneum.
Our Copper-based Technology
Do you want to learn more about our CuTraceTM technology platform that fuels our pipeline? Click here.
Diagnostic Nuclide
Makes tumors and metastases visible
Therapeutic Nuclide
Destroys tumors and metastases